@article{articlea5d8796d,
title   = {Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial},
author = {Ramacciotti, Eduardo and Agati, Leandro Barile and Calderaro, Daniela and Aguiar, Valéria Cristina Resende and Spyropoulos, Alex C and Oliveira, Caroline Candida Carvalho de and Santos, Jessica Lins dos and Volpiani, Giuliano Giova and Sobreira, Marcone Lima and Joviliano, Edwaldo Edner and Bohatch Júnior, Milton Sérgio and Fonseca, Benedito Antonio Lopes da and Ribeiro, Maurício Serra and Dusilek, Cesar and Itinose, Kenji and Sanches, Suzanna Maria Viana and Ramos, Karine de Almeida Araujo and Moraes, Nara Franzin de and Tierno, Paulo Fernando Guimarães Morando Marzocchi and Oliveira, André Luiz Menezes de and Tachibana, Adriano and Chate, Rodrigo Caruso and Santos, Marcus Vinícius Barbosa and Cavalcante, Bruno Bezerra de Menezes and Moreira, Ricardo Cesar Rocha and Chiann, Chang and Tafur, Alfonso and Fareed, Jawed and Lopes, Renato D and MICHELLE investigators},
year = {2022},
doi = {10.1016/S0140-6736(21)02392-8},
journal   = {The Lancet}
}